Calcium/Calmodulin-dependent Protein Kinase Kinase 2 (CAMKK2) acts as a signaling hub, receiving signals from various regulatory pathways and decoding them via phosphorylation of downstream protein kinases -such as AMPK (AMP-activated protein kinase) and CAMK types I and IV. CAMKK2 relevance is highlighted by its constitutive activity being implicated in several human pathologies. However, at present, there are no specific small-molecule inhibitors available for this protein kinase. Moreover, CAMKK2 and its closest human homologue, CAMKK1, are thought to have overlapping biological roles. Here we present six novel costructures of CAMKK2 bound to potent ligands identified from a library of ATP-competitive kinase inhibitors. Isothermal titration calorimetry (ITC) revealed that binding to some of these molecules is enthalpy driven. We expect our results to further advance current efforts to discover small molecule kinase inhibitors specific to each human CAMKK.
Introduction
The Calcium/calmodulin-dependent kinases (CAMKs) respond to increases in the intracellular concentration of Ca 2+ and play important roles in several cellular processes, mainly via the activation of transcription factors. These enzymes share a modular architecture composed of a kinase domain (KD) followed by an auto-inhibitory sequence and a partially overlapping calmodulin-binding domain (CBD). CAMKs are usually kept in an inactive state through autoinhibition, which can be relieved, upon increases in Ca 2+ levels, through the interaction of the protein CBD with Ca 2+ /calmodulin 1 . CAMK family members include CAMK1-4 and two CAMK kinases (CAMKK1-2). As mediators of the second messenger effects of Ca 2+ , CAMK family members play prominent roles in cell division (CAMK3 aka eEF-2K -eukaryotic elongation factor 2 kinase); neuronal development (CAMK1, 2 and 4) and immune response (CAMK4) 2, 3 .
CAMK kinases (CAMKK) 1 and 2 are Ser/Thr kinases and upstream regulators of CAMKs [4] [5] [6] . For example, CAMKKs phosphorylate and activate CAMK1 and CAMK4, resulting in the activation of cyclic AMP-responsive element binding protein (CREB). Consequently, both CAMKKs participate in several processes within the nervous system, such as neurite elongation and branching, longterm potentiation and memory 7, 8 .
In addition to regulating CAMK family members, CAMKK2 can phosphorylate AMP-activated protein kinase (AMPK). AMPK is a heterotrimeric protein complex that acts as an energy sensor and plays a key role regulating cellular energy metabolism. Dysregulation of AMPK has been implicated in major chronic diseases, such as obesity, inflammation, diabetes and cancer 9 .
AMPK activity can be allosterically controlled via competitive binding of different adenine nucleotides (ATP, ADP or AMP) to its regulatory gamma subunit 10, 11 . Alternatively, AMPK activation can be triggered by CAMKK2 via a nucleotide-independent mechanism. Thus, CAMKK2
can decode increases in intracellular Ca 2+ levels triggered by upstream extracellular events, such as insulin receptor binding, to activate AMPK and maintain energy levels [12] [13] [14] . Accordingly, CAMKK2-null mice are protected against weight gain induced by a high-fat diet, insulin resistance and glucose intolerance 13 .
The development of potent and specific small molecule inhibitors to each of the CAMKKs would have a significant impact on our ability to investigate the roles these enzymes play in various biological processes. Due to the high degree of sequence and structure similarity between CAMKK1 and CAMKK2
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, it is not surprising that most CAMKK inhibitors are equally potent against both enzymes 16 . Moreover, STO-609 17 , a commonly used inhibitor of CAMKKs,
demonstrates IC50 values less than 250 nM for six other kinases when screened against a panel of only 92 protein kinases 18 . Thus, despite progress, the invention of a specific inhibitor for either CAMKK remains elusive.
Here we characterized the interaction of the kinase domain of CAMKK2 with several commercially available, small molecule kinase inhibitors. Our ITC data suggest that binding of the most potent compounds is enthalpy driven. We have also obtained co-crystal structures for CAMKK2 bound to some of these compounds. These co-structures suggest possible strategies for the development of CAMKK2-specific inhibitors.
Results and Discussion

DSF -Identification of kinase inhibitors that bind to CAMKK2
We employed a thermal-shift assay (Differential Scanning Fluorimetry, DSF) 19 to identify compounds that can bind strongly to the kinase domain of CAMKK2. DSF screens were performed on purified CAMKK2 kinase domain (KD) (Supplementary Figure S1) Table 2) .
For all co-structures the electron density maps were of good quality and allowed unambiguous building of the small molecule ligands within the protein ATP-binding site ( An overlay of all 6 co-structures revealed that the overall structure of CAMKK2-KD is mostly unchanged, despite being bound to different ligands. The most notable exception to this observation concerned the position of the protein P-loop. The P-loop is an inherently flexible (GxGxF/YG conserved motif) region of the kinase domain that folds over the phosphate atoms from the ATP molecule. For the different CAMKK2-KD co-structures obtained here, the distance between C-α atoms from P-loop residue Ser175 varied as much as 6.7 Å. We also observed a small change in the position of the α-C helix when bound to TAE-226 compared to the other costructures (1.3 Å towards the ligand, Glu236 Cα-atom position) ( Figure 3A ). In all co-structures of CAMKK2-KD obtained here, the protein displayed an active (α-C-in) conformation, in which the R-spine is fully formed. The R-spine is a set of 4 residue in kinases whose hydrophobic side chains line up to form a spine when the enzyme is in an active conformation 23 .
Despite the high resolution of these co-structures, we could not completely build the region between β-3 and α-C (residues 206-229). This region is known as the RP-insert and is rich in proline (8 out of 24), glycine (5 out of 24) and arginine (5 out of 24) residues, and likely to be disordered. The related human kinase, CAMMK1, also displays a similarly disordered region 15 .
We compared our CAMKK2-KD co-crystal structures to those obtained for the same protein bound to STO-609 (PDB ID 2ZV2) 22 and a recently-developed azaindazole inhibitor similar to GSK650394 (PDB ID 6CMJ) 16 . Overlay of all small molecules in the CAMKK2 ATP-binding site reveals that future compounds could explore the addition of polar groups to take place of the structural water molecules found trapped between the inhibitors and the conserved glutamate from the protein α-C helix ( Figure 3B ). Using inhibitor atoms to satisfy polar interactions originally facilitated between protein groups and crystallographic water molecules has been used successfully to increase compound potency in a number of cases. For example, Kung and colleagues used this strategy to increase the potency of compounds targeting HSP90 24 .
Nevertheless, potent inhibitors against both CAMKK proteins do exist 16, 17 and a priority to better understand the function of these two proteins might be the development of specific inhibitors of each enzyme. Recently, our group obtained the structure of CAMKK1 and proposed structural differences between the 2 CAMKKs that could be exploited for the design of specific molecules to each protein. One of these strategies included taking advantage of the extra space observed for hinge residue Val270 in CAMKK2 15 . This suggestion that was also put forward by Price and colleagues 16 .
Favorable enthalpy dominates binding of most potent ligands to CAMKK2-KD
We performed ITC to confirm our DSF results and assess the thermodynamic parameters of ligand binding. We found that top hits on the DSF -BI 2536, ALK-IN-1, BI 6727 and GSK650394;
were all potent binders of CAMKK2 and had KD values ranging from 4.4 to 23.3 nM (Fig. 4) . Particular experimental conditions, such as the different buffers, enzymes and substrates employed in these experiments might be behind these differences.
Binding of all assayed compounds to CAMKK2-KD was enthalpy-driven, which is usually associated with the presence of hydrogen bonds and van der Waals interactions between ligand and protein 25, 26 . Indeed, all three compounds for which we obtained both ITC data and co-crystal structures (BI 2536, ALK-IN-1 and GSK650394) engaged the protein hinge region via two hydrogen bonds. These non-covalent interactions could account for the enthalpy values observed in our ITC experiments (ranging from -58.5 to -28.5 kJ/mol - Table 3 ). The fourth compound we obtained ITC data for, BI 6727, was originally described as a PLK1 inhibitor and interacts with its target enzyme via two hydrogen bonds to the protein hinge region 27 . This compound is a close analogue of BI 2536, for which we were able to solve a structure. Assuming BI 6727 binding mode to CAMKK2-KD is the same as the one observed for PLK1 and comparable to our BI 2536 CAMKK2 structure, the enthalpy-driven interaction observed for this compound (-40.1 kJ/mol - Table 3 ) and CAMKK2-KD may also be explained by the formation of hydrogen bonds.
Conclusion
In conclusion we present here 6 novel co-structures of CAMKK2-KD bound to potent ligands selected from a library of ATP-competitive kinase inhibitors. Our co-structures showed that CAMKK2-KD had a similar binding mode with all ligands and point to possible design strategies for the invention of more potent and selective CAMKK2 inhibitors. An inhibitor specific for CAMKK2 would be able to set apart the biological functions of each one of the CAMKKs and further illuminate the different roles CAMKK2 plays in energy metabolism and in the nervous system.
Methods:
Cloning, protein expression and purification
For crystallization of CAMKK2, we employed a construct of CAMKK2 isoform 7 residues 161-449
(NCBI NP_001257415.1 -SGC construct CAMKK2B-cb002) containing the wild-type kinase domain (CAMKK2-KD) in vector pNIC28-Bsa4. The construct was transformed into Escherichia coli BL21(DE3) cells that co-express λ-phosphatase and three rare tRNAs (plasmid pACYC-LIC+) 28 . The cells were cultured in TB medium containing 50 µg/mL kanamycin and 34 µg/mL chloramphenicol at 37 °C with shaking until the OD600 reached ~3 and then cooled to 18°C for 1 Table 2 .
Diffraction data was integrated with XDS 29 and scaled using AIMLESS from the CCP4 software suite 30 . The structure was solved by molecular replacement using Phaser 31 and the kinase domain of CAMKK2 as the search model (PDB ID 2ZV2) 22 . Refinement was performed using REFMAC5 32 and Coot 33 was used for model building. Structure validation was performed using 96-well format -Each well contained 20 μL of 2 μM kinase in 10 mM HEPES pH 7.5 and 500 mM NaCl. SYPRO Orange dye (Invitrogen) was used in 5X as final concentration.
The compounds, previously solubilized in DMSO, were used at 12 µM final concentration and 2.5% DMSO. Plates were sealed using optically clear films and transferred to an Agilent Mx3005p
RT-PCR machine (Agilent). The fluorescence intensity was measured during a temperature gradient from 25 to 95 °C at a constant rate of 0.05 °C/s, and protein melting temperatures were calculated based on a Boltzmann function fitting to experimental data (Graphpad Prism 7).
Protein in 2.5% DMSO was used as a reference.
For both formats, compounds that caused a shift in melting temperature of the protein (ΔTm) of 2 °C or higher compared to the reference were considered positive hits.
Isothermal titration calorimetry
Measurements were made using a MicroCal AutoITC200 (Malvern, United Kingdom), at 20 °C with 1,000 rpm stirring. For all measurements CAMKK2-KD protein was dialyzed overnight against gel filtration buffer, and the dialysis buffer was used to dilute the inhibitors. CAMKK2- Table  1 and Supplemental Table S1 . Tables   Table 1 - 
